VYNE compared with RLYB: revenue, margins and what each company keeps, and the suppliers and customers both name

VYNEVYNE Therapeutics Inc.

Mkt capRevenueRevenue

RLYBRallybio Corp

Mkt capRevenueRevenue

Compare

VYNEVYNE Therapeutics Inc.

RLYBRallybio Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

VYNE revenue flow unavailable. RLYB: latest quarter is a loss; flow not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only VYNE 0

None

Shared 0

No disclosed counterparties: VYNE.

Only RLYB 9

JNJJohnson & Johnson, through its wholly-owned subsidiary, Momenta Pharmaceuticals, Inc. ("J&J")customer

RXRXRecursioncustomer

SNYKymab Limited (Sanofi)supplier

ABCLAbCellera Biologicssupplier

5 more · RLYB chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

VYNEVYNE Therapeutics Inc.

17.86▼−10.24%· post 17.86

Mkt cap—Revenue—Revenue—

RLYBRallybio Corp

15.51▼−0.19%· post 15.61

ClosedNov 2 '26

Mkt cap$84.9MRevenue$212,000Q1 FY26Revenue$858,000FY25

Compare

ClosedNov 2 '26

VYNEVYNE Therapeutics Inc.

RLYBRallybio Corp

17.86▼−10.24%post 17.86

Price

15.51▼−0.19%post 15.61

—

Mkt cap

$84.9M

—

Revenue

$212,000Q1 FY26

—

Revenue

$858,000FY25

VYNE17.86▼−10.24%vsRLYB15.51▼−0.19%ClosedNov 2 '26

Price

rebased to 0%

VYNE, solidRLYB, dashed